Phase I study to assess safety, biodistribution and radiation dosimetry for 89 Zr-girentuximab in patients with renal cell carcinoma.

Autor: Merkx RIJ; Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands. Robin.Merkx@radboudumc.nl.; Department of Urology, Radboudumc, Nijmegen, The Netherlands. Robin.Merkx@radboudumc.nl., Lobeek D; Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., Konijnenberg M; Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands., Jiménez-Franco LD; ABX-CRO advanced pharmaceutical services, Dresden, Germany., Kluge A; ABX-CRO advanced pharmaceutical services, Dresden, Germany., Oosterwijk E; Department of Urology, Radboudumc, Nijmegen, The Netherlands., Mulders PFA; Department of Urology, Radboudumc, Nijmegen, The Netherlands., Rijpkema M; Department of Medical Imaging: Nuclear Medicine, Radboudumc, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, The Netherlands.
Jazyk: angličtina
Zdroj: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2021 Sep; Vol. 48 (10), pp. 3277-3285. Date of Electronic Publication: 2021 Mar 02.
DOI: 10.1007/s00259-021-05271-w
Abstrakt: Purpose: In this phase I study, we evaluated the safety, biodistribution and dosimetry of [ 89 Zr]Zr-DFO-girentuximab ( 89 Zr-girentuximab) PET/CT imaging in patients with suspicion of clear cell renal cell carcinoma (ccRCC).
Methods: Ten eligible patients received an intravenous administration of 37 MBq (± 10%) of 89 Zr-girentuximab at mass doses of 5 mg or 10 mg. Safety was evaluated according to the NCI CTCAE (version 4.03). Biodistribution and normal organ dosimetry was performed based on PET/CT images acquired at 0.5, 4, 24, 72 and 168 h post-administration. Additionally, tumour dosimetry was performed in patients with confirmed ccRCC and visible tumour uptake on PET/CT imaging.
Results: 89 Zr-girentuximab was administered in ten patients as per protocol. No treatment-related adverse events ≥ grade 3 were reported. 89 Zr-girentuximab imaging allowed successful differentiation between ccRCC and non-ccRCC lesions in all patients, as confirmed with histological data. Dosimetry analysis using OLINDA/EXM 2.1 showed that the organs receiving the highest doses (mean ± SD) were the liver (1.86 ± 0.40 mGy/MBq), the kidneys (1.50 ± 0.22 mGy/MBq) and the heart wall (1.45 ± 0.19 mGy/MBq), with a mean whole body effective dose of 0.57 ± 0.08 mSv/MBq. Tumour dosimetry was performed in the 6 patients with histologically confirmed ccRCC resulting in a median tumour-absorbed dose of 4.03 mGy/MBq (range 1.90-11.6 mGy/MBq).
Conclusions: This study demonstrates that 89 Zr-girentuximab is safe and well tolerated for the administered activities and mass doses and allows quantitative assessment of 89 Zr-girentuximab PET/CT imaging in patients with suspicion of ccRCC.
Trial Registration: NCT03556046-14th of June, 2018.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: